

 참고 문헌

1. Abdel-Aleem H, D'arcangues C, Vogelsong KM, Gaffield ML, Gulmezoglu AM. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. *Cochrane Database Syst Rev* 2013; 10: CD003449.
2. Abou-Setta A, Houston B, Al-Inary HG, Farquhar C. Levonorgestrel-releasing intrauterine device (LNG-IUS) for symptomatic endometriosis following surgery. *Cochrane Database Syst Rev* 2013; 31: CD005072
3. Ämmälä M, Nyman T, Strengell L, Rutanen E-M. Effect of intrauterine contraceptive devices on cytokine messenger ribonucleic acid expression in the human endometrium. *Fertil Steril* 1995; 63: 773-8.
4. Andersson K, Od Lind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. *Contraception* 1994; 49: 56-72.
5. Baldszti E, Wimmer-Puchinger B, Loschke K. Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study. *Contraception* 2003; 67: 87-91.
6. Barbosa I, Olsson SE, Od Lind V, Goncalves T, Coutinho E. Ovarian function after seven years' use of levonorgestrel IUD. *Adv Contracep* 1995; 11: 85-95.
7. Castellsague X, Thompson WD, Dubrow R. Intra-uterine contraception and the risk of endometrial cancer. *Int J Cancer* 1993; 54: 911-16.
8. Celen S, Möröy P, Sucak A, Aktulay A, Danisman N. Clinical outcomes of early postplacental insertion of intrauterine contraceptive devices. *Contraception* 2004; 69: 279-82.
9. Centers for Disease Control and Prevention. U.S. medical eligibility criteria for contraceptive use, 2010. *MMWR Recomm Rep* 2010; 59: 1-86.
10. Chaim W, Mazor M. Pregnancy with an intrauterine device in situ and preterm delivery. *Arch Gynecol Obstet* 1992; 252: 21-4.
11. Cho S, Nam A, Kim H, Chay D, Park K, Cho DJ, et al. Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis. *Am J Obstet Gynecol* 2008; 198: 373.e1-7.
12. Committee on Practice Bulletins-Gynecology, Long-Acting Reversible Contraception Work Group. Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. *Obstet Gynecol* 2017; 130(5): e251-e269.
13. Conz L, Mota BS, Bahamondes L, Doria MT, Derchain SFM, Rieira R, et al., Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis. *Acta Obstet Gynecol Scand* 2020; 99: 970-82.
14. Cheng L, Gulmezoglu AM, Oel CJ, Piaggio G, Ezcurra E, Van Look PFA. Interventions for emergency contraception. *Cochrane Database Syst Rev* 2004; CD001324.
15. Critchley HO, Wang H, Jones RL, Kelly RW, Drudy TA, Gebbie AE, et al. Morphological and functional features of endometrial decidualization following longterm intrauterine levonorgestrel delivery. *Hum Reprod* 1998; 13: 1218-24.
16. Depypere H, Inki P. The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review. *Climacteric* 2015; 18: 470-82.
17. Farley MM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. *Lancet* 1992; 339: 785-8.
18. Faundes A, Telles E, Cristofolletti MI, Faundes D, Castro S, Hardy E. The risk of inadvertent intrauterine device insertion in women carriers of endocervical Chlamydia trachomatis. *Contraception* 1998; 58: 105-9.
19. Foreman H, Stadel BV, Schlesselman S. Intrauterine device usage and fetal loss. *Obstet Gynecol* 1981; 58: 669-77.

20. Fraser IS. Non-contraceptive health benefits of intrauterine hormonal systems. *Contraception* 2010; 82: 396-403.
21. Fraser IS. The promise and reality of the intrauterine route for hormone delivery for prevention and therapy of gynecological disease. *Contraception* 2007; 75: S112-7.
22. FSRH Guideline (February 2021) Progestogen-only Implant. *BMJ Sex Reprod Health* 2021; 47: 1-62.
23. Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and meta-analysis. *Am J Obstet Gynecol* 2012; 207: 266.e1-12.
24. Garder FJE, Konje JC, Abrams KR, Brown LJ, Ai-Azzawi F, Bell SC, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: A randomized controlled trial. *Lancet* 2000; 356: 1711-7.
25. Gronlund B, Blaabjerg J. Serious intestinal complication five years after insertion of a Nova-T. *Contraception* 1991; 44: 517-20.
26. Hidalgo MM, Hidalgo-Regina C, Bahamondes V, Monteiro I, Petta CA, Bahamondes L. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. *Contraception* 2009; 80: 84-9.
27. Hov GG, Skjeldestad FE, Hilstad T. Use of IUD and subsequent fertility – follow-up after participation in a randomized clinical trial. *Contraception* 2007; 75: 88-92.
28. Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkila A, Walker JJ, Cameron IT. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. *Br J Obstet Gynaecol* 1998; 105: 592-8.
29. Jonsson B, Landgren B-M, Eneroth P. Effects of various IUDs on the composition of cervical mucus. *Contraception* 1991; 43: 447-58.
30. Koch UJ. Sperm migration in the human female genital tract with and without intrauterine devices. *Acta Eur Fert* 1980; 2: 33-60.
31. Lockhat FB, Emembolu JE, Konje JC. Serum and peritoneal fluid levels of levonorgestrel in women with endometriosis who were treated with an intrauterine contraceptive device containing levonorgestrel. *Fertil Steril* 2005; 83: 398-404.
32. Makinen JL, Erkkola RU, Laippala PJ. Causes of the increase in incidence of ectopic pregnancy – a study on 1017 patients from 1966 to 1985 in Turku, Finland. *Am J Obstet Gynecol* 1989; 160: 642-6.
33. Mansour D, Bahamondes L, Critchley H, Darney P, Fraser IS. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. *Contraception*. 2011; 83(3): 202-10.
34. Moray KV, Chaurasia H, Sachin O, Joshi B. A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant. *Reprod Health*. 2021; 18(1): 4.
35. Morin-Papunen L, Martikainen H, McCarthy MI, Franks S, Sovio U, Hartikainen AL, et al. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population. *Am J Obstet Gynecol* 2008; 199: 529.e1-529.e10.
36. Orbo A, Vereide A, Arnes M, Pettersen I, Straue B. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. *BJOG* 2014; 121: 477-86.
37. Ortiz ME, Croxatto HB, Bardin CW. Mechanisms of action of intrauterine devices. *Obstet Gynecol Surv* 1996; 51: S42-S51.
38. Paterson H, Ashton J, Harrison-Woolrych M. A nationwide cohort study of the use of the levonorgestrel intrauterine device in New Zealand adolescents. *Contraception* 2009; 79: 433-8.
39. RCOG with BSGE. Management of Endometrial Hyperplasia. Green-top Guideline No. 67. RCOG/BSGE Joint Guideline. 1st ed. London: RCOG; 2016. pp. 1-30.
40. Schlaff WD, Carson SA, Luciano A, Ross D, Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. *Fertil Steril*. 2006; 85: 314-25.
41. Shoupe D, Kjos SL. *Current Clinical Practice: The Handbook of Contraception: A Guide for Practical Management*, 2nd ed. Totowa, NJ: Human Press; 2006. Chapter 9, Implantable Contraception; pp. 139-64.
42. Sivin I, Stern J, Coutinho E, Mattos CER, El Mahgoub S, Diaz S, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the copper T380 Ag IUDs. *Contraception* 1991; 44: 473-80.
43. Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20 years. *Contraception* 2007; 75: S70-S75.
44. Skjeldestadt FE, Bratt H. Fertility after complicated and non-complicated use of IUDs. A controlled prospective study. *Adv Contracept* 1988; 4: 179-84.
45. Skouby SO, Molsted-Pedersen L, Kosonen A. Consequences of intrauterine contraception in diabetic women. *Fertil Steril* 1984; 42: 568-72.
46. Stoddard A, McNicholas C, Peipert J. Efficacy and safety of long-acting reversible contraception. *Drugs* 2011; 71: 969-80.

47. Thonneau P, Almont T, de La Rochebrochard E, Maria B. Risk factors for IUD failure: results of a large multicentre case-control study. *Hum Reprod* 2006; 21: 2612-6.
48. Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Nelson AL, et al, (eds), *Contraceptive Technology* (20th revised edn). New York, NY: Ardent Media, 2011.
49. Turok DK, Gawron LM, Lawson S. New developments in long-acting reversible contraception: the promise of intrauterine devices and implants to improve family planning services. *Fertil Steril*. 2016;106(6):1273-81.
50. Veldhuis HM, Vos AG, Lagro-Janssen ALM. Complications of the intrauterine device in nulliparous and parous women. *Eur J Contracept Reprod Health Care* 2004; 10: 82-7.
51. Walsh T, Grimes D, Freziers R, Nelson A, Bernstein L, Coulson A, et al. Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices. *Lancet* 1998; 351: 1005-8.
52. Wang Y, Yang M, Huang X, Li X, Lin E, Feng Y. Prevention of benign endometrial polyp recurrence using a lenonorgestrel-releasing intrauterine system in premenopausal patients: A retrospective cohort study. *J Minim Invasive Gynecol* 2020; 27: 1271-6.
53. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. *Contraception*. 2003; 68: 75–87.
54. Zhao G, Li M, Zhu P, Xu R, Wang J, Xu R. A preliminary morphometric study on the endometrium from patients treated with indomethacin-releasing copper intrauterine device. *Hum Reprod* 1997; 12: 1563-6.
55. Zhou S, Chi IC. Immediate postpartum IUD insertions in a Chinese hospital – A two-year follow-up. *Int J Gynaecol Obstet* 1991; 35: 157.